York, United Kingdom, 1 October 2009.
Pro-Cure Therapeutics Ltd (Pro-Cure), a world leader in the development of novel therapeutics targeting cancer stem cells, today announced that Dr Alastair J. Riddell has been appointed to the role of Non-executive Chairman, replacing Brian Greenwood who will step down as Chairman.
Dr Mick McLean, the company CEO, commented ''The Board is highly appreciative of the leadership and important contribution made by Brian, who has led the company through a period of significant change and positioned it for future growth. Alastair joins the Board to provide leadership and support for the executive management team, as we continue to build Pro-Cure into a therapeutic development company. He brings with him deep experience at Board level in building biotechnology companies and generating value realization for shareholders. He joins Pro-Cure at a very exciting time in our evolution, and I'm delighted to work alongside him.''
Dr Riddell said ''Brian has helped create the managerial and financial foundation for this early stage of development for Pro-Cure. The company is now poised to take its discovery programmes in novel prostate cancer targets and therapeutics from York to the world stage. I am looking forward to helping the company achieve this. The focus will be on maximising commercial and shareholder value from its leading edge, cancer stem cell technology over the next few years. We shall do this by collaboration with major pharmaceutical companies backed by long term investment.''
Brian Greenwood said ''It has been a privilege to lead such an incredibly talented and dedicated team over the past 2½ years and now is the right time to hand over the role. I am extremely proud of the progress Pro-Cure has made during my tenure as Chairman, and with Alastair taking over the role, he will be able to add significant incremental value and I know that the company will be in very safe hands going forward.''
Dr Riddell has previously been the CEO of Pharmagene plc, Paradigm Therapeutics Ltd and Stem Cell Sciences plc. He is a main Board member of the BioIndustry Association (BIA) of Great Britain and recently a Non-Executive Director of CXR Biosciences Ltd.